Sai Life Sciences (SAILIFE) investor relations material

Executive summary

• Q2 FY27 revenue grew 23% YoY, supported by growth across CRO and CDMO; EBITDA margin was 28%.

• Customer relationships are expanding from individual projects into strategic engagements spanning discovery, development and manufacturing; two large-pharma relationships are now strategic engagements.

Financial highlights

• Consolidated Q2 revenue was ₹6,585.85 million, up from ₹5,374.70 million YoY; net profit was ₹983.17 million, versus ₹838.44 million.

• H1 consolidated revenue was ₹12,128.70 million, versus ₹10,338.89 million; net profit was ₹1,716.02 million, versus ₹1,442.99 million.

• Q2 EBITDA, including forex, was ₹187 Cr, up 20% YoY; PAT was ₹98 Cr, up 17% YoY. H1 EBITDA and PAT each rose 19% YoY to ₹335 Cr and ₹172 Cr, respectively.

• Q2 material margin was ₹484 Cr, up 22% YoY; consolidated profit before exceptional items and tax was ₹1,312.80 million in Q2 and ₹2,292.54 million in H1.

• Standalone Q2 revenue was ₹6,470.82 million and net profit was ₹960.13 million, versus ₹5,266.69 million and ₹829.49 million YoY.

Outlook and guidance

• H2 FY27 is expected to be stronger than H1, supported by pipeline progression and the ramp-up of new capacity; no numerical growth guidance was given.

• FY27 CapEx remains planned at ₹1,100–1,300 Cr; H1 investment was ₹621 Cr, including ₹358 Cr in Q2.

• Strategic engagement growth is expected over time, but timing and revenue contribution depend on customer needs and execution; no revenue or wallet-share guidance was given.